Valerie Combaret

Summary

Affiliation: Institut Paoli-Calmettes
Country: France

Publications

  1. ncbi No evidence for involvement of SDHD in neuroblastoma pathogenesis
    Katleen De Preter
    Center for Medical Genetics, Ghent University Hospital, K5, De Pintelaan 185, B 9000 Ghent, Belgium
    BMC Cancer 4:55. 2004
  2. ncbi Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions
    Frederique Ponchel
    Molecular Medicine Unit, University of Leeds, Leeds, UK
    BMC Biotechnol 3:18. 2003
  3. ncbi Determination of 17q gain in patients with neuroblastoma by analysis of circulating DNA
    Valerie Combaret
    Centre Leon Berard, Laboratoire de Recherche Translationnelle, Lyon Cedex, France
    Pediatr Blood Cancer 56:757-61. 2011
  4. ncbi Influence of neuroblastoma stage on serum-based detection of MYCN amplification
    Valerie Combaret
    Centre Leon Berard, Laboratoire de Recherche Translationnelle, Lyon, France
    Pediatr Blood Cancer 53:329-31. 2009
  5. ncbi Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity
    Valerie Combaret
    Laboratoire de Recherche Translationnelle, Centre Leon Berard, Lyon, France
    Mol Cancer 7:50. 2008
  6. ncbi Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients
    Valerie Combaret
    Centre Leon Berard, 69008 Lyon, France
    Cancer Res 62:3646-8. 2002
  7. ncbi Protein chip array profiling analysis of sera from neuroblastoma patients
    Valerie Combaret
    Centre Leon Berard, Unité d Oncologie Moléculaire, 28 rue Laennec 69008 Lyon France, Universite Claude Bernard Lyon I, 8 avenue Rockefeller 69008, Lyon, France
    Cancer Lett 228:91-6. 2005
  8. ncbi Analysis of genomic alterations in neuroblastoma by multiplex ligation-dependent probe amplification and array comparative genomic hybridization: a comparison of results
    Valerie Combaret
    Centre Leon Berard, Laboratoire de Recherche Translationnelle, Lyon, France
    Cancer Genet 205:657-64. 2012
  9. ncbi High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplification
    Anne Laprie
    Département d Hémato Oncologie, Hopital des Enfants, Toulouse, France
    Cancer 101:1081-9. 2004
  10. ncbi [Immunotherapy of poor-prognosis neuroblastoma in children: from bench to bedside]
    Raphael Rousseau
    Service de Pediatrie, Centre Leon Berard, Lyon, France
    Bull Cancer 93:153-61. 2006

Collaborators

Detail Information

Publications11

  1. ncbi No evidence for involvement of SDHD in neuroblastoma pathogenesis
    Katleen De Preter
    Center for Medical Genetics, Ghent University Hospital, K5, De Pintelaan 185, B 9000 Ghent, Belgium
    BMC Cancer 4:55. 2004
    ..In this study, we sought for evidence for involvement of SDHD in neuroblastoma...
  2. ncbi Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions
    Frederique Ponchel
    Molecular Medicine Unit, University of Leeds, Leeds, UK
    BMC Biotechnol 3:18. 2003
    ..Though this so-called 'TaqMan' approach has proved easy to optimise in practice, the dual-labelled probes are relatively expensive...
  3. ncbi Determination of 17q gain in patients with neuroblastoma by analysis of circulating DNA
    Valerie Combaret
    Centre Leon Berard, Laboratoire de Recherche Translationnelle, Lyon Cedex, France
    Pediatr Blood Cancer 56:757-61. 2011
    ..As the gain of chromosome arm 17q is the most frequent chromosome alteration reported in NB primary tumors, we evaluated the presence of this 17q gain in the peripheral blood of patients with NB...
  4. ncbi Influence of neuroblastoma stage on serum-based detection of MYCN amplification
    Valerie Combaret
    Centre Leon Berard, Laboratoire de Recherche Translationnelle, Lyon, France
    Pediatr Blood Cancer 53:329-31. 2009
    ..High copy numbers are strongly associated with rapid tumor progression and poor outcome, independently of tumor stage or patient age, and this has become an important factor in treatment stratification...
  5. ncbi Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity
    Valerie Combaret
    Laboratoire de Recherche Translationnelle, Centre Leon Berard, Lyon, France
    Mol Cancer 7:50. 2008
    ..Recently, bortezomib has been identified as an effective inhibitor of neuroblastoma cell growth and angiogenesis...
  6. ncbi Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients
    Valerie Combaret
    Centre Leon Berard, 69008 Lyon, France
    Cancer Res 62:3646-8. 2002
    ....
  7. ncbi Protein chip array profiling analysis of sera from neuroblastoma patients
    Valerie Combaret
    Centre Leon Berard, Unité d Oncologie Moléculaire, 28 rue Laennec 69008 Lyon France, Universite Claude Bernard Lyon I, 8 avenue Rockefeller 69008, Lyon, France
    Cancer Lett 228:91-6. 2005
    ..In support of this observation, high SAA levels were detected by ELISA in the sera of patients with poor prognosis neuroblastoma. Based on this finding, promises and limitations of the approach are discussed...
  8. ncbi Analysis of genomic alterations in neuroblastoma by multiplex ligation-dependent probe amplification and array comparative genomic hybridization: a comparison of results
    Valerie Combaret
    Centre Leon Berard, Laboratoire de Recherche Translationnelle, Lyon, France
    Cancer Genet 205:657-64. 2012
    ..Because of the higher sensitivity and specificity of genome-wide information, reasonable cost, and shorter time of aCGH analysis, we recommend the aCGH procedure for the analysis of genomic alterations in neuroblastoma...
  9. ncbi High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplification
    Anne Laprie
    Département d Hémato Oncologie, Hopital des Enfants, Toulouse, France
    Cancer 101:1081-9. 2004
    ..The objective of this study was to determine whether systemic and regional, intensified treatment can improve the outcome of children who present with a localized neuroblastoma (NB) with MYCN amplification (MNA)...
  10. ncbi [Immunotherapy of poor-prognosis neuroblastoma in children: from bench to bedside]
    Raphael Rousseau
    Service de Pediatrie, Centre Leon Berard, Lyon, France
    Bull Cancer 93:153-61. 2006
    ....
  11. ncbi Characterization of rearrangements involving the ALK gene reveals a novel truncated form associated with tumor aggressiveness in neuroblastoma
    Alex Cazes
    INSERM U830, Institut Curie, Centre de Recherche, Paris, France
    Cancer Res 73:195-204. 2013
    ..These results indicate that genomic rearrangements constitute an alternative mechanism to ALK point mutations resulting in receptor activation...